Hyperpolarization-activated cyclic nucleotide-gated channels and ventricular arrhythmias in heart failure: A novel target for therapy?

Journal of the American Heart Association

Volumn 2, Issue 3, 2013, Pages

  Dias, Priyanthi ^a   Terracciano, Cesare M ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC NUCLEOTIDE GATED CHANNEL; IVABRADINE; METOPROLOL; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL;

ACTION POTENTIAL; BETA ADRENERGIC STIMULATION; CELL COMMUNICATION; DRUG MECHANISM; ECHOCARDIOGRAPHY; EDITORIAL; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE FIBROSIS; HEART MUSCLE PERFUSION; HEART RATE; HEART RHYTHM; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE REMODELING; HUMAN; HYPERPOLARIZATION; PRIORITY JOURNAL; SYSTOLIC HEART FAILURE; ANIMAL; ARRHYTHMIAS, CARDIAC; BIOSYNTHESIS; COMPLICATION; HEART VENTRICLE; METABOLISM; ARRHYTHMIAS; EDITORIALS; FUNNY CURRENT; HCN CHANNELS; NOTE;

ANIMALS; ARRHYTHMIAS, CARDIAC; HEART FAILURE; HEART VENTRICLES; HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNELS;

ARRHYTHMIAS; EDITORIALS; FUNNY CURRENT; HCN CHANNELS; HEART FAILURE; IVABRADINE;

EID: 84889093994     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.113.000287     Document Type: Editorial

References (20)

1. Goldberger JJ, Buxton AE, Cain M, Costantini O, Exner DV, Knight BP, Lloyd-Jones D, Kadish AH, Lee B, Moss A, Myerburg R, Olgin J, Passman R, Rosenbaum D, Stevenson W, Zareba W, Zipes DP. Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation. 2011;123:2423-2430.
2. Kuwabara Y, Kuwahara K, Takano M, Kinoshita H, Arai Y, Yasuno S, Nakagawa Y, Igata S, Usami S, Minami T, Yamada Y, Shibata J, Nishikimi T, Ueshima K, Nakao K. Increased expression of HCN channels in the ventricular myocardium contributes to enhanced arrhythmicity in mouse failing hearts. J Am Heart Assoc. 2013;2:e000150.
3. DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res. 2010;106:434-446.
4. Cerbai E, Pino R, Sartiani L, Mugelli A. Influence of postnatal-development on I(f) occurrence and properties in neonatal rat ventricular myocytes. Cardiovasc Res. 1999;42:416-423.
5. Cerbai E, Pino R, Porciatti F, Sani G, Toscano M, Maccherini M, Giunti G, Mugelli A. Characterization of the hyperpolarization-activated current, I(f), in ventricular myocytes from human failing heart. Circulation. 1997;95:568-571.
6. Stillitano F, Lonardo G, Zicha S, Varro A, Cerbai E, Mugelli A, Nattel S. Molecular basis of funny current (If) in normal and failing human heart. J Mol Cell Cardiol. 2008;45:289-299.
7. Fernandez-Velasco M, Goren N, Benito G, Blanco-Rivero J, Bosca L, Delgado C. Regional distribution of hyperpolarization-activated current (If) and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts. J Physiol. 2003; 553:395-405.
8. Cerbai E, Sartiani L, DePaoli P, Pino R, Maccherini M, Bizzarri F, DiCiolla F, Davoli G, Sani G, Mugelli A. The properties of the pacemaker current I(F)in human ventricular myocytes are modulated by cardiac disease. J Mol Cell Cardiol. 2001;33:441-448.
9. Hofmann F, Fabritz L, Stieber J, Schmitt J, Kirchhof P, Ludwig A, Herrmann S. Ventricular HCN channels decrease the repolarization reserve in the hypertrophic heart. Cardiovasc Res. 2012;95:317-326.
10. Luo X, Lin H, Pan Z, Xiao J, Zhang Y, Lu Y, Yang B, Wang Z. Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem. 2008;283:20045-20052.
11. Kuwahara K, Saito Y, Takano M, Arai Y, Yasuno S, Nakagawa Y, Takahashi N, Adachi Y, Takemura G, Horie M, Miyamoto Y, Morisaki T, Kuratomi S, Noma A, Fujiwara H, Yoshimasa Y, Kinoshita H, Kawakami R, Kishimoto I, Nakanishi M, Usami S, Saito Y, Harada M, Nakao K. NRSF regulates the fetal cardiac gene program and maintains normal cardiac structure and function. EMBO J. 2003;22:6310-6321.
12. Postea O, Biel M. Exploring HCN channels as novel drug targets. Nat Rev Drug Discov. 2011;10:903-914.
13. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807-816.
14. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875-885.
15. Tardif JC, O'Meara E, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L, Swedberg K. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507-2515.
16. Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, Gnecchi-Ruscone T, Pittalis M, De AL, Baruscotti M, Gaeta M, Furlanello F, Di FD, Lupo PP. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012;60:1323-1329.
17. Milliez P, Messaoudi S, Nehme J, Rodriguez C, Samuel JL, Delcayre C. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol. 2009;296:H435-H441.
18. Ceconi C, Comini L, Suffredini S, Stillitano F, Bouly M, Cerbai E, Mugelli A, Ferrari R. Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am J Physiol Heart Circ Physiol. 2011;300: H366-H373.
19. Navaratnarajah M, Ibrahim M, Siedlecka U, van Doom C, Shah A, Gandhi A, Dias P, Sarathchandra P, Yacoub MH, Terracciano CM. Influence of ivabradine on reverse remodelling during mechanical unloading. Cardiovasc Res. 2013;97:230-239.
20. Roubille F, Tardif JC. New therapeutic targets in cardiology: heart failure and arrhythmia: HCN channels. Circulation. 2013;127:1986-1996.